$ACT Recent Headlines Pharma love triangle is
Post# of 89351
Posted On: 10/05/2014 11:44:01 AM
$ACT Recent Headlines
Pharma love triangle is a win, win, win for investors 1:11 p.m. Oct. 2, 2014 - The Trading Deck
In focus: Finally, a breakdown 7:41 p.m. Oct. 1, 2014 - Lawrence G. McMillan
In focus: Back in the trading range 2:27 p.m. Sept. 24, 2014 - Lawrence G. McMillan
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Actavis's Salix play undermines Allergan defense 11:43 a.m. Sept. 24, 2014 - Russ Britt
Actavis reportedly in talks to buy Salix Pharma 11:42 a.m. Sept. 24, 2014 - Russ Britt
Actavis shares rise on report of Pfizer approach 2:49 p.m. Sept. 23, 2014 - Ciara Linnane
Botox maker Allergan rejected Actavis takeover bid 6:18 p.m. Sept. 22, 2014 - Jonathan D. Rockoff
In focus: Market giving mixed signals 7:03 p.m. Sept. 17, 2014 - Lawrence G. McMillan
DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis raises guidance as earnings top views 8:11 a.m. Aug. 5, 2014 - MarketWatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Leon Cooperman talks up Citi, Thermo Fisher 11:20 a.m. July 16, 2014 - Sue Chang
Leon Cooperman likes Thermo Fisher, Citi, Actavis 11:06 a.m. July 16, 2014 - Sue Chang
10 biggest S&P 500 winners and losers for 2014 10:44 a.m. July 1, 2014 - Philip van Doorn
Affiliated Managers Group to join S&P 500 5:33 p.m. June 24, 2014 - Wallace Witkowski
10 best-performing S&P 500 stocks of 2014 2:38 p.m. June 2, 2014 - Philip van Doorn
Pfizer's plan to relocate after merger deal draws lawmakers' fire 11:30 a.m. May 9, 2014 - Russ Britt
Corner drug store may move overseas to save on taxes 6:31 a.m. April 16, 2014 - Al Lewis
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
Salix Seen as Target After Scrapping Tax Inversion Cosmo Purchase 12:07 p.m. Oct. 3, 2014 - TheStreet.com
Salix Cancels Tax Inversion, Opens Way For Buyers 10:11 a.m. Oct. 3, 2014 - Investors Business Daily
Wall Street Breakfast: 83M Accounts Exposed In JPMorgan Data Breach 6:31 a.m. Oct. 3, 2014 - Seeking Alpha
Bloomberg: Salix in talks with Actavis, Allergan deal fades 6:16 p.m. Oct. 2, 2014 - Seeking Alpha
Top Fund Buys: Chipotle, Allergan, Jazz, Gilead 5:25 p.m. Oct. 2, 2014 - Investors Business Daily
Actavis in Patent Infringement Lawsuit for Purdue's Butrans - Analyst Blog 5:20 p.m. Oct. 1, 2014 - Zacks.com
A Bizarre Pharma Love Triangle 4:00 p.m. Oct. 1, 2014 - Seeking Alpha
Ardelyx Bowel Drug Could Rival Actavis' Linzess 11:10 a.m. Oct. 1, 2014 - Investors Business Daily
Zogenix submits sNDA for abuse deterrent Zohydro 10:37 a.m. Oct. 1, 2014 - Seeking Alpha
Ireland Exporters Look To Thursday's ECB Policy Vote 5:24 p.m. Sept. 30, 2014 - Investors Business Daily
Top 10 Dow Dividend Stocks For October 9:39 a.m. Sept. 30, 2014 - InvestorPlace.com
AMGN, ACT And GILD, Pushing Drugs Industry Downward 1:03 p.m. Sept. 29, 2014 - TheStreet.com
Bullish on Tech, Drug, Online Ed, and Solar 11:44 a.m. Sept. 29, 2014 - Barrons.com
Allergan Reiterates Opposition to Valeant Bid 8:41 a.m. Sept. 29, 2014 - The Wall Street Journal Interactive Edition
More concerns surface over Allergan's new bid 6:44 a.m. Sept. 28, 2014 - Seeking Alpha
T. Rowe Price Urges Allergan to Put Acquisitions to a Vote 10:54 p.m. Sept. 26, 2014 - The Wall Street Journal Interactive Edition
Meet 5 Top Stocks With Rising Earnings Estimates 7:02 a.m. Sept. 26, 2014 - Investors Business Daily
Trade-Ideas: Actavis (ACT) Is Today's New Lifetime High Stock 9:47 a.m. Sept. 25, 2014 - TheStreet.com
Dow Index Overseers Make It Official: U.S. Firms Only 8:43 p.m. Sept. 24, 2014 - The Wall Street Journal Interactive Edition
Facebook, Three Other Leaders In Striking Distance 5:08 p.m. Sept. 24, 2014 - Investors Business Daily
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents 7:30 a.m. Oct. 2, 2014 - GlobeNewswire
Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast 8:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Actavis Confirms Generic Butrans® Patent Challenge 4:05 p.m. Sept. 25, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 10:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 9:39 a.m. Sept. 24, 2014 - PR Newswire - PRF
Twenty Employers to Attend Annual Life Science Hiring Event Next Week 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers 9:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension 5:10 p.m. Sept. 9, 2014 - PR Newswire - PRF
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte 8:55 a.m. Sept. 9, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product 8:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 9:20 a.m. Sept. 2, 2014 - PR Newswire - PRF
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 9:10 a.m. Aug. 29, 2014 - PR Newswire - PRF
Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 4:05 p.m. Aug. 26, 2014 - PR Newswire - PRF
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 11:15 a.m. Aug. 19, 2014 - PR Newswire - PRF
Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI) 7:24 a.m. Aug. 19, 2014 - PR Newswire - PRF
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42 7:00 a.m. Aug. 5, 2014 - PR Newswire - PRF
Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Pharma love triangle is a win, win, win for investors 1:11 p.m. Oct. 2, 2014 - The Trading Deck
In focus: Finally, a breakdown 7:41 p.m. Oct. 1, 2014 - Lawrence G. McMillan
In focus: Back in the trading range 2:27 p.m. Sept. 24, 2014 - Lawrence G. McMillan
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Actavis's Salix play undermines Allergan defense 11:43 a.m. Sept. 24, 2014 - Russ Britt
Actavis reportedly in talks to buy Salix Pharma 11:42 a.m. Sept. 24, 2014 - Russ Britt
Actavis shares rise on report of Pfizer approach 2:49 p.m. Sept. 23, 2014 - Ciara Linnane
Botox maker Allergan rejected Actavis takeover bid 6:18 p.m. Sept. 22, 2014 - Jonathan D. Rockoff
In focus: Market giving mixed signals 7:03 p.m. Sept. 17, 2014 - Lawrence G. McMillan
DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis raises guidance as earnings top views 8:11 a.m. Aug. 5, 2014 - MarketWatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Leon Cooperman talks up Citi, Thermo Fisher 11:20 a.m. July 16, 2014 - Sue Chang
Leon Cooperman likes Thermo Fisher, Citi, Actavis 11:06 a.m. July 16, 2014 - Sue Chang
10 biggest S&P 500 winners and losers for 2014 10:44 a.m. July 1, 2014 - Philip van Doorn
Affiliated Managers Group to join S&P 500 5:33 p.m. June 24, 2014 - Wallace Witkowski
10 best-performing S&P 500 stocks of 2014 2:38 p.m. June 2, 2014 - Philip van Doorn
Pfizer's plan to relocate after merger deal draws lawmakers' fire 11:30 a.m. May 9, 2014 - Russ Britt
Corner drug store may move overseas to save on taxes 6:31 a.m. April 16, 2014 - Al Lewis
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
Salix Seen as Target After Scrapping Tax Inversion Cosmo Purchase 12:07 p.m. Oct. 3, 2014 - TheStreet.com
Salix Cancels Tax Inversion, Opens Way For Buyers 10:11 a.m. Oct. 3, 2014 - Investors Business Daily
Wall Street Breakfast: 83M Accounts Exposed In JPMorgan Data Breach 6:31 a.m. Oct. 3, 2014 - Seeking Alpha
Bloomberg: Salix in talks with Actavis, Allergan deal fades 6:16 p.m. Oct. 2, 2014 - Seeking Alpha
Top Fund Buys: Chipotle, Allergan, Jazz, Gilead 5:25 p.m. Oct. 2, 2014 - Investors Business Daily
Actavis in Patent Infringement Lawsuit for Purdue's Butrans - Analyst Blog 5:20 p.m. Oct. 1, 2014 - Zacks.com
A Bizarre Pharma Love Triangle 4:00 p.m. Oct. 1, 2014 - Seeking Alpha
Ardelyx Bowel Drug Could Rival Actavis' Linzess 11:10 a.m. Oct. 1, 2014 - Investors Business Daily
Zogenix submits sNDA for abuse deterrent Zohydro 10:37 a.m. Oct. 1, 2014 - Seeking Alpha
Ireland Exporters Look To Thursday's ECB Policy Vote 5:24 p.m. Sept. 30, 2014 - Investors Business Daily
Top 10 Dow Dividend Stocks For October 9:39 a.m. Sept. 30, 2014 - InvestorPlace.com
AMGN, ACT And GILD, Pushing Drugs Industry Downward 1:03 p.m. Sept. 29, 2014 - TheStreet.com
Bullish on Tech, Drug, Online Ed, and Solar 11:44 a.m. Sept. 29, 2014 - Barrons.com
Allergan Reiterates Opposition to Valeant Bid 8:41 a.m. Sept. 29, 2014 - The Wall Street Journal Interactive Edition
More concerns surface over Allergan's new bid 6:44 a.m. Sept. 28, 2014 - Seeking Alpha
T. Rowe Price Urges Allergan to Put Acquisitions to a Vote 10:54 p.m. Sept. 26, 2014 - The Wall Street Journal Interactive Edition
Meet 5 Top Stocks With Rising Earnings Estimates 7:02 a.m. Sept. 26, 2014 - Investors Business Daily
Trade-Ideas: Actavis (ACT) Is Today's New Lifetime High Stock 9:47 a.m. Sept. 25, 2014 - TheStreet.com
Dow Index Overseers Make It Official: U.S. Firms Only 8:43 p.m. Sept. 24, 2014 - The Wall Street Journal Interactive Edition
Facebook, Three Other Leaders In Striking Distance 5:08 p.m. Sept. 24, 2014 - Investors Business Daily
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents 7:30 a.m. Oct. 2, 2014 - GlobeNewswire
Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast 8:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Actavis Confirms Generic Butrans® Patent Challenge 4:05 p.m. Sept. 25, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 10:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 9:39 a.m. Sept. 24, 2014 - PR Newswire - PRF
Twenty Employers to Attend Annual Life Science Hiring Event Next Week 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers 9:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension 5:10 p.m. Sept. 9, 2014 - PR Newswire - PRF
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte 8:55 a.m. Sept. 9, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product 8:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 9:20 a.m. Sept. 2, 2014 - PR Newswire - PRF
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 9:10 a.m. Aug. 29, 2014 - PR Newswire - PRF
Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 4:05 p.m. Aug. 26, 2014 - PR Newswire - PRF
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 11:15 a.m. Aug. 19, 2014 - PR Newswire - PRF
Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI) 7:24 a.m. Aug. 19, 2014 - PR Newswire - PRF
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42 7:00 a.m. Aug. 5, 2014 - PR Newswire - PRF
Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
(0)
(0)